Cardiovascular Information System Market Analysis, Size, Growth and Forecast to 2023
The global cardiovascular information system market is witnessing significant growth due to increasing prevalence of cardiovascular diseases, growing government initiates towards electronic health record system implementation and growing rate of medication errors. The remote access to data and images, and reduced IT burden in the diagnostic center and hospitals are supporting the demand of CVIS. Moreover, better interoperability and increasing healthcare cost are further expected to boost the market. Based on mode of operation, web-based segment leads the global market in terms of size, owing to high rate of awareness, improved interoperability, reduced IT burden in hospitals and relatively less cost. Based on component, the market for service segment is expected to grow at the fastest rate during the forecast period, due to upgradation of services for the complex software introduction and requirement for extensive training.
Explore Report at: https://www.psmarketresearch.com/market-analysis/cardiovascular-information-system-market
The increasing demand for cloud based solutions is expected to create opportunities for the players in the market. The unexplored market in developing economies is also creating abundant opportunities for the cardiovascular information system market to grow at a significant rate in the coming years. However, high cost of cardiovascular information, lack of standard healthcare protocol towards implementation of CVIS solution in developing countries and reluctance of healthcare provides to implement cardiovascular information system are the key factors hampering the growth of the global market.
Cardiovascular disease is the disease of heart and blood vessels, which includes conditions such as hypertension, coronary heart disease, heart failure, cerebrovascular disease and rheumatic heart disease. It is the leading cause of premature death around the world. According to the WHO, globally about 17.5 million people died due to cardiovascular diseases in 2012, while the number is expected to reach 23.3 million by 2030.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/cardiovascular-information-system-market/toc-sample
The key players operating in the global cardiovascular information system market are Philips Healthcare, McKesson Corporation, Philips Healthcare, General Electric Company, Siemens AG, AGFA Healthcare and Cerner Corporation.
Alzheimer’s Disease Pipeline Analysis, 2017 - Clinical Trials & Results and Other Developments
The study analyzed that the Alzheimer’s disease pipeline comprises 89 drug candidates in different stages of development.
As per the findings of the research, majority of the active drug candidates of Alzheimer’s disease pipeline are being developed to be administered by oral route.
Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis
AC Immune, Ltd. is using SupraAntigen technology platform for the development of Crenezumab, ACI-24 and ACI-35 for Alzheimer's disease. This technology is used to produce conformation specific antibodies and is used to create products for active immunization (vaccines) and passive immunization (antibodies).
The research finds that different companies have collaborated for the development of Alzheimer’s disease pipeline. In March 2014, Eisai Co., Ltd. and Biogen Idec collaborated to develop and commercialize two of Eisai's clinical candidates, E2609 and BAN2401, for Alzheimer’s disease.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis/report-sample
Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., and others.
Oral Mucositis Therapeutics Pipeline Analysis, 2017 - Collaboration and Other Developments
The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis
Oragenics, Inc. is using ActoBiotics technology platform for the development of their drug candidates for the treatment of oral mucositis. The technology platform produces a new class of orally delivered biopharmaceuticals. Through ActoBiotics technology platform, food-grade microbes are engineered to generate biologically contained ActoBiotics therapeutics for in situ expression and secretion of novel proteins and peptides including cytokines, enzymes, hormones and monoclonal antibodies within the body.
The research also found that various companies received designations from the USFDA for the development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA granted Fast Track designation to AG013 for the treatment of oral mucositis.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample
Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.
Restless Legs Syndrome Market Analysis, Size, Growth and Forecast to 2023
Restless legs syndrome or RLS is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
To know more about “Restless Legs Syndrome Market” visit: https://www.psmarketresearch.com/market-analysis/restless-legs-syndrome-market
Restless legs syndrome increases at night when the patient is at rest. RLS are common in both, male and female; however the disease has its highest impact on woman who are elderly or in some cases woman with the age 35 to 50 years. Some of the most common symptoms of the restless legs syndrome are continue itching and pain in the legs, and unusual sleep pattern. The restless legs syndrome affects the quality of life of the person suffering from the disease.
The exact reason behind the restless legs syndrome is not known precisely, however, it is believed the disease is caused due to genetic factors or due to iron deficiency in the brain or due to the disorders in dopaminergic balance.
Request for TOC of “Restless Legs Syndrome Market” at: https://www.psmarketresearch.com/market-analysis/Restless-Legs-Syndrome-Market/toc-sample
The exact treatment of this disease is not present till now. However the available drug in the market helps in the indicative treatment of the disease. Some of the drug in the restless legs syndrome market such as sulfonamide by safinamide by Newron Pharmaceuticals reduces the symptoms by novel action such as potent, reversible and selective inhibition of MAO-B, without disturbing the MAO-A and dopamine uptake. This enhances the glutamate release and dopaminergic function of the patients; it also reduces the dopamine degradation. One other drug: SER-214 manufacture by Serina is used widely in the restless legs syndrome treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology this drug can be combined with the polymer and transported to the patients.
Some of the major players operating in the global restless legs syndrome market include, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA.
Hospital Infection Therapeutics Market Size, Development, Growth and Forecast to 2023
The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.
North America leads the hospital infection therapeutics market followed by Europe. The North America hospital infection therapeutics market leads, due to improved healthcare awareness, high ratio of hospitals as compared to population of the region, increasing count of multi drug resistant microbial pathogens and increase in aging population of the region. Asia-Pacific is growing with an exponential rate, due to increased incidences of hospital infections and high demands of therapeutic drugs in the emerging countries such India and China.
Explore more about “Hospital Infection Therapeutics Market” at: https://www.psmarketresearch.com/market-analysis/hospital-infection-therapeutics-market
Hospital acquired infections are caused produced by viral pathogens, fungal and bacterial. Most of the hospital infections crop up from intensive care units. Varied range of hospital infections are being treated by various antimicrobial drugs. The patients staying in the hospitals develop several infections during their treatment. . The infections are known as hospital-acquired infections or hospital infections. The hospital acquired infections spread in the hospitals, rehabilitation centers, outpatient surgery centers, nursing homes and dialysis centers.
Some of the pipeline drugs available in the market for hospital acquired infections are MK-3415A, Amikacin Inhale, Oritavancin, Surotomycin, Ceftolozane, Dalvance, Plazomicin, Eravacycline, Tedizolid, Delafloxacin, and CAZ AVI. In 2011, according to the centers for disease control and prevention, around 1.6 million hospital acquired infections have been reported from all types of bacteria in US every year. Additionally, in 2013 about 4 million patients were identified with hospital acquired infections in Europe.
Request Table of Contents: https://www.psmarketresearch.com/market-analysis/Hospital-Infection-Therapeutics-Market/toc-sample
Some of the competitors in the hospital infection therapeutics market are: Cubist Pharmaceuticals, Inc., Actavis PLC, Johnson & Johnson Services, Inc., Bayer AG, GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Pfizer, Inc. and Sanofi.
Bioinformatics Market Analysis, Size, Development, Growth and Forecast to 2023
The introduction and adoption of cloud computing and nanopore technology are expected to offer numerous opportunities in the global bioinformatics market. The nanopore technology has been projected for getting used in the study of crop science, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins and small molecules with a range of applications in personalized medicine, and scientific research.
To know more visit: https://www.psmarketresearch.com/market-analysis/bioinformatics-market
Bioinformatics is a discipline that deals with the retrieval, storage, processing, management and analysis of organic information through computational techniques. Bioinformatics plays an important role in drug innovation and improvement. The involvement of bioinformatics in storing, retrieving, analyzing and forming biological information helps in efficiently managing enormous database associated with drug innovation and development.
The global bioinformatics market can be broadly segmented on the basis of applications, products and services, sectors and geographies. On the basis of products & services the bioinformatics market can be broadly bifurcated into bioinformatics platforms, bioinformatics knowledge management tools and bioinformatics services. The bioinformatics knowledge management tools segment can be further divided into specialized tools and generalized tools. The bioinformatics platforms are further sub-divided into sequence alignment platforms, sequence analysis platforms, structural & functional analysis platforms and sequence manipulation platforms. The bioinformatics services segment is again segmented into database & management, sequencing services and data analysis.
Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Bioinformatics-Market/toc-sample
North America dominated the global bioinformatics market in 2013, by holding approximately 42% of the market share. The availability of encouraging government support in terms of funding and large number of research initiatives carried out in the region are some of the factors responsible for worldwide dominance of the region. The Asia-Pacific bioinformatics market is projected to be the fastest growing regional market in the forecast period. High availability of trained labors in countries such as, China and India with low labor costs has inspired manufacturers to stick upon contract research outsourcing strategies for limiting costs, which has enormously contributed to the growth of Asia-Pacific bioinformatics market.
Some of the key competitors within the global bioinformatics market include Tripos, LP, Affymetrix, Inc, Agilent Technologies, Illumina, Inc., Helicos Biosciences Corporation, IBM Life Sciences, Thermo Fisher Scientific Inc, Rosetta Inpharmatics LLC, Celera and others.
Amyotrophic Lateral Sclerosis Pipeline Analysis 2017 - Clinical Trials & Results, Patent and Other Developments
The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 69 drug candidates, of which one drug candidate is in Phase III stage, 16 drug candidates are in Phase II stage, nine drug candidates are in Phase I stage, 32 drug candidates are in Pre-Clinical stage, five candidates are inactive and six drug candidates are in discontinued stage. Amyotrophic lateral sclerosis is a neurodegenerative disorder in brain and spinal cord, the progression of the disease can further lead to muscles getting enough nourishments, which can further cause atrophy of the muscles. Amyotrophic Lateral Sclerosis occurs mostly in the lateral region of the body, in which spinal cord reflexes are too intense. This can also lead to scarring and hardening of the muscles into that region. Various new therapies and advanced technologies are driving the growth of Amyotrophic lateral sclerosis pipeline.
Explore Report Overview at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis
As per the findings of the research, around 31.0% of drug candidates for the treatment of amyotrophic lateral sclerosis pipeline are being developed to be administered by oral route, 4.0% by intravenous route, 48.0% are not disclosed and 17.0% are to be administered by other routes which includes subcutaneous, intraperitoneal, sublingual, inhalation and intramuscular.
The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan. Dainippon Sumitomo Pharma Co., Ltd. received exclusive research, development and commercial rights in Japan for EPI-743 and EPI-589. Edison Pharmaceuticals, Inc. received $35.0 million in an upfront payment and $15.0 million as research and development support fee. In addition, Edison Pharmaceuticals, Inc. also received $10.0 to $35.0 million in milestone payments per indication associated with successful development. After the launch, Edison Pharmaceuticals, Inc. received royalties based on sales amounts and up to $460.0 million in milestone payments in accordance with sales goals.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis/report-sample
Many companies are developing Amyotrophic lateral sclerosis drug candidates in different phases. Cytokinetics, Inc., AB Science, F. Hoffman La-Roche AG, FlexPharma, Inc., Orion Corporation, Omeros Corporation, Genervon Biopharmaceuticals, LLC, Edison Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and various other companies have their Amyotrophic lateral sclerosis drug candidates in different stages of development. Cytokinetics, Inc. has drug candidate in Phase III clinical stage.
Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, Orphazyme ApS, Edison Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and Cytokinetics, Inc.
